Brain-based interventions for eating disorders are moving beyond one-size-fits-all approaches, as clinicians now have measurable indicators to predict which patients will benefit most from neurofeedback therapy. This precision medicine advance could transform treatment selection for the estimated 2.8 million Americans struggling with binge-eating disorder.
A controlled trial examining 47 adults with clinically diagnosed binge-eating disorder revealed distinct neurophysiological signatures that forecast treatment success. Participants showing heightened high beta brainwave activity (23-28 Hz) in frontal-central regions when viewing food images, combined with lower baseline activity during cognitive control tasks, achieved superior outcomes including reduced binge episodes and sustained abstinence. The study utilized both EEG monitoring and real-time functional near-infrared spectroscopy across 12 neurofeedback sessions over eight weeks.
This represents a significant methodological advancement in eating disorder treatment, where therapeutic decisions have traditionally relied on clinical observation rather than objective biomarkers. The ability to identify neurophysiological response patterns addresses a critical gap in personalized psychiatry, particularly for conditions involving dysregulated reward and control circuits. However, the relatively small sample size and predominantly female cohort limit generalizability, while the mechanisms underlying these predictive patterns remain unclear. The findings suggest neurofeedback may work best for individuals with specific attention-regulation profiles, potentially sparing non-responders from ineffective treatments while directing them toward more suitable interventions. This biomarker-guided approach could substantially improve treatment efficiency in clinical practice.